|
|
|
|
|
31.10.25 - 12:03
|
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025 (Business Wire)
|
|
|
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2025 and provide a business update on November 3, 2025.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For...
|
|
|
|
|
|
|
|
|
|
|
07.08.25 - 13:03
|
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
- Continued rapid progress with Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV for Hepatitis B; Announced safety and efficacy for Cohort 1 and safety data for Cohort 2
- PBGENE-HBV demonstrated substantial antiviral activity in all Cohort 1 patients, with best responses achieving a 47-69% reduction in Hepatitis B surface antigen (HBsAg) and durable HBsAg reduction in one patient 7 months after initial dose administration
- Accelerated development of PBGENE-DMD as a potential first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD)
- Granted FDA Rare Pediatric Disease Designation and Orphan Drug Designation for PBGENE-DMD for the treatment of DMD; Clinical data expected in 2026.
- Extended expected cash runway to the second half of 2027 providing more than two years of operating cashDURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap...
|
|
|
04.08.25 - 13:06
|
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025 (Business Wire)
|
|
|
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.05.25 - 13:06
|
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
- Announced new clinical data for two programs utilizing ARCUS validating safety and efficacy for Precision's in vivo gene editing approach
- Announced initial data from first cohort in the ongoing Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV; initial safety data presented at EASL; ongoing clinical updates anticipated throughout 2025
- Received regulatory clearance of IND from the U.S. FDA to expand ELIMINATE-B trial and CTA approved by MHRA for study expansion into the UK. Additionally, PBGENE-HBV granted U.S. FDA Fast Track Designation for chronic Hepatitis B (HBV)
- Accelerating PBGENE-DMD within Precision pipeline to be first-in-class in vivo gene editing approach addressing majority of Duchenne's Muscular dystrophy (DMD) patients; targeting to file IND/CTA in 2025 with clinical data in 2026
- Expected cash runway into second half of 2026 enabling data read outs from first two wholly owned in vivo gene editing programs – PBGENE-HBV and PBGENE-DMD
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioScie...
|
|
|
|
|
08.05.25 - 13:06
|
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 (Business Wire)
|
|
|
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. Fo...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
